Brief: Immunicum Secures Partner On Potential Production Of DCP-001
18/10/2022 07:09
Oct 18 (Reuters) - Mendus AB (publ) IMMUN.ST :
* SECURES MANUFACTURING PARTNER FOR ESTABLISHING POTENTIAL
PIVOTAL
TRIAL-STAGE AND COMMERCIAL PRODUCTION OF DCP-001
* ANNOUNCED AGREEMENT TO ENABLE TECHNOLOGY TRANSFER FOR
MANUFACTURING OF CO'S LEAD DEVELOPMENT PROGRAM DCP-001 WITH
MINARIS REGENERATIVE MEDICINE
* PLANS TO ANNOUNCE UPDATED RESULTS, SURVIVAL OUTCOMES FROM
ADVANCE II CLINICAL TRIAL EVALUATING ITS LEAD CANCER PROGRAM
DCP-001 AS NOVEL AML MAINTENANCE THERAPY IN Q4 2022
Source text: https://mfn.se/one/a/mendus/mendus-ab-mendus-secures-manufacturing-partner-for-establishing-potential-pivotal-trial-stage-and-commercial-production-of-dcp-001-176a946e
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))